Latest Global Expansion News

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.

Close the Loop Limited has ended acquisition discussions with Adamantem Capital but remains confident in its standalone growth strategy, projecting steady revenue and an EBITDA range of $11m-$13m for the first half of 2025.

Pureprofile Limited has upgraded its FY25 financial guidance following a robust first half, highlighted by a 22% revenue increase and a 30% surge in Q2, driven by strong international expansion and automation adoption.

Advanced Braking Technology Ltd (ASX: ABV) reported a robust 24% increase in product sales revenue for Q2 FY25, driven by international expansion and the launch of its innovative BrakeiQ system. The company’s underlying profit also grew by 25%, underscoring operational efficiencies and a strong global pipeline.

Spacetalk Ltd reports robust growth in paid mobile subscribers and annual recurring revenue for Q2 FY25, underpinned by strategic international expansion and disciplined cost management.

Cardiex Limited has commenced U.S. deliveries of its CONNEQT Pulse arterial health monitor alongside the launch of its companion CONNEQT App, marking a pivotal expansion into the American digital health market.

Hydrix Limited has extended its contract with Paul Hartmann AG, adding $2.8 million in revenue and reinforcing its international growth strategy.

First Graphene Limited strengthens its financial footing with a UK R&D tax rebate and expands its global footprint through new distribution agreements in India and Brazil.

Close the Loop Limited has concluded its exclusivity period with Adamantem Capital without signing binding transaction documents, leaving the potential acquisition uncertain. Shareholders are advised to await further updates as discussions remain open but no deal is confirmed.

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.